About Advent Life Sciences

• Founded: 2006

• Headquarters: London, United Kingdom

• Strategy: Early-stage life sciences, therapeutics and diagnostics, Europe

• Thesis: Backs companies developing transformative medicines and diagnostics, typically at seed through Series B, focusing on portfolio construction across modalities and disease areas to balance risk

• Track record: Prior funds include Fund I (2008, £50m), Fund II (2011, £100m), Fund III (2014, £145m), and Fund IV (2019, £200m)

• Leadership: Co-founded by Shahzad Malik and Chris Hollowood

The British Business Bank has committed up to £135m across two Advent Life Sciences funds, contributing to the institution's growing life sciences allocation, which now approaches £750m. The commitment spans both Advent's latest flagship vehicle and a continuation fund structure. The British Business Bank's expanding presence in life sciences reflects sustained UK policy support for the sector, particularly at earlier stages where dilution and capital efficiency remain persistent concerns.

The £135m commitment is the British Business Bank's largest single backing of a life sciences manager to date. That scale signals confidence in Advent's portfolio construction — the firm typically writes initial cheques of £3m–£8m and reserves heavily for follow-ons, a model that requires substantial fund size to support a 15–20 company portfolio through multiple financing rounds. The continuation fund element is notable: it allows Advent to extend hold periods on assets that need more time to reach clinical milestones or exit windows, addressing a structural mismatch in European biotech between development timelines (often 8–12 years seed to exit) and traditional fund lives.

The British Business Bank's total life sciences commitments nearing £750m create an interesting pressure point. That capital is spread across multiple managers, but concentration risk builds as the same UK-based LPs (including the British Business Bank itself) anchor successive funds in a relatively small ecosystem. Whether Advent can deploy £135m at pace without competing against its own prior funds for deals — or without shifting up-market into later stages where it lacks track record — is the question the next 18 months will answer.

Source: AltAssets